Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCTB35 in Systemic Lupus Erythematosus
NCT06841042Phase 2Recruiting
- Sponsor
- Sinocelltech Group Limited
- Start
- Feb 2025
- Primary completion
- May 2027
- Modality
- Bispecific Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of SCTB35 in systemic lupus erythematosus (SLE), sponsored by Sinocelltech Group Limited. Primary endpoints: Incidence rate of adverse event (AE) at 24 weeks and Systemic Lupus Erythematosus Responder Index-4 at 24 weeks. Started Feb 2025; status: recruiting.
02
Drugs
SCTB35
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT06841042.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06841042.